Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide (BI 456906) Phase 2 in NASH and Fibrosis
NCT04771273Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Primary completion
- Nov 2023
- Modality
- Peptides
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial of survodutide in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Improvement From Baseline in Liver Histological Findings Based on Liver Biopsy at 48 weeks. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04771273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771273.